News Focus
News Focus
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

Re: tinkershaw post# 7163

Saturday, 10/29/2011 3:33:01 PM

Saturday, October 29, 2011 3:33:01 PM

Post# of 20689

…bring to market drugs. Far more profitable the protected drug market vs. a royalty or licensing fee.

Quite so. MNTA certainly does not intend to become the Rambus of the follow-on-biologics universe.

Insofar as most prospective players in the US FoB arena are intending to develop non-substitutable biosimilars via the 351(k) pathway or the conventional BLA pathway, it’s not even clear that MNTA’s patents on cell lines would be able to block anybody else’s products from reaching the market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”